10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness

Iris Acquisition Corp files an amended 10-Q/A to restate its financials for the period ended June 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.

Summary

• Iris Acquisition Corp is filing an amendment to its quarterly report on Form 10-Q/A for the period ended June 30, 2024, to restate its unaudited condensed consolidated financial statements.
• The restatement is due to a material related party transaction involving a loan of approximately $1.216 million from Hana Immunotherapeutics LLC, an affiliate of Liminatus Pharma's CEO, to Gaius Investment Partners, the buyer of the managing member of Iris Acquisition Holdings, LLC (the Sponsor).
• The company identified an additional material weakness in internal control over financial reporting in connection with the restatement.
• Management concluded that the company's disclosure controls and procedures were not effective as of June 30, 2024, due to this material weakness.
• The company's initial business combination agreement with Liminatus Pharma has been amended multiple times, with the current outside date set to September 3, 2024.
• As of June 30, 2024, the company had $339,203 of cash in its operating bank account and a working capital deficit of approximately $6,059,539.
• The company has extended the time to complete the initial Business Combination to September 9, 2024.
• The company's management has determined that the company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the company's ability to continue as a going concern.
• The company may need to obtain additional financing either to complete its initial Business Combination or because it becomes obligated to redeem a significant number of its public shares upon consummation of its initial Business Combination.

Sentiment

Score: 3

Explanation: The document reveals significant issues including a restatement due to a related party transaction, a material weakness in internal controls, and a going concern warning. These factors negatively impact investor confidence.

Positives

• The company is taking steps to remediate the identified material weaknesses in internal control over financial reporting.
• The company has expanded and improved its review process for complex securities and related accounting standards.
• The company has increased communication among its personnel and third-party professionals with whom it consults regarding complex accounting applications.
• The company is establishing additional monitoring and oversight controls designed to ensure the accuracy and completeness of its financial statements and related disclosures.
• The company plans to hire consultants to prepare and complete the filing of its tax returns.

Negatives

• The company is restating its financials for the period ended June 30, 2024, due to a material related party transaction.
• The company identified an additional material weakness in internal control over financial reporting.
• The company's disclosure controls and procedures were not effective as of June 30, 2024, due to this material weakness.
• As of June 30, 2024, the company had a working capital deficit of approximately $6,059,539.
• The company's management has determined that the company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to complete its initial business combination is uncertain.
• The company may need to obtain additional financing to complete its initial business combination or to meet its obligations after the business combination.
• The company's management has determined that the company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of June 30, 2024, due to a material weakness in internal control over financial reporting.
• The company is subject to a new U.S. federal 1% excise tax on certain repurchases of stock, which could reduce the value of the company's Class A common stock or cash available for a business combination or liquidation.

Future Outlook

The company's ability to continue as a going concern is dependent on completing a business combination by September 9, 2024, and may require additional financing.

Industry Context

The document reflects challenges faced by SPACs, including regulatory scrutiny, the need to secure financing, and the pressure to complete business combinations within specified timeframes. The restatement and disclosure of material weaknesses highlight the importance of robust internal controls and compliance in the SPAC industry.

Comparison to Industry Standards

• The disclosure of a material weakness in internal control is a significant issue that would likely raise concerns among investors and regulators.
• Compared to industry best practices, the company's internal controls appear to be deficient, requiring remediation efforts.
• Other SPACs, such as Churchill Capital Corp IV (CCIV) and Pershing Square Tontine Holdings (PSTH), have faced scrutiny and challenges related to their business combinations, highlighting the risks and complexities involved in the SPAC process.
• The need for multiple extensions to the business combination deadline is not uncommon in the SPAC industry, but it adds uncertainty and pressure to the process.

Related Party Transactions

• A loan of approximately $1.216 million from Hana Immunotherapeutics LLC, an affiliate of Liminatus Pharma's CEO, to Gaius Investment Partners, the buyer of the managing member of Iris Acquisition Holdings, LLC (the Sponsor), was not disclosed in previous filings.

Stakeholder Impact

• Shareholders face increased risk due to the restatement, material weakness, and going concern warning.
• Employees may experience uncertainty regarding the company's future.
• The target company, Liminatus Pharma, is affected by the uncertainty surrounding the business combination.
• Creditors face increased risk due to the company's financial condition and going concern warning.

Next Steps

• The company needs to complete its business combination by September 9, 2024.
• The company needs to remediate the identified material weaknesses in internal control over financial reporting.
• The company needs to file a post-effective amendment to ParentCo's Registration Statement on Form S-4 to disclose the change to Liminatus's business and to reschedule a previously scheduled meeting of stockholders to a later date.
• The Board has determined to seek stockholder approval to extend the date by which we have to complete an initial business combination beyond September 9, 2024, to December 31, 2024.

Key Dates